==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb

This page displays user query in tabular form.

Th1185 details
Primary information
ID1766
ThPP IDTh1185
Therapeutic Peptide/Protein NameHuman clostridium tetani toxoid immune globulin
SequenceNA view full sequnce in fasta
Functional ClassificationIIIb
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half LifeNA
DescriptionNA
Indication/DiseaseIt is indicated for prophylaxis against tetanus following injury in patients whose immunization is incomplete or uncertain (see below). It is also indicated, although evidence of effectiveness is limited, in the regimen of treatment of active cases of tetanus.
PharmacodynamicsIt supplies passive immunity to those individuals who have low or no immunity to the toxin produced by the tetanus organism, Clostridium tetani. The antibodies act to neutralize the free form of the powerful exotoxin produced by this bacterium.
Mechanism of ActionNA
ToxicityNA
MetabolismNA
AbsorptionNA
Volume of DistributionNA
ClearanceNA
CategoriesNA
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetNA
Information of corresponding available drug in the market
Brand NameNA
CompanyNA
Brand DiscriptionNA
Prescribed forNA
Chemical NameNA
FormulationNA
Physcial AppearanceNA
Route of AdministrationNA
Recommended DosageNA
ContraindicationNA
Side EffectsNA
Useful Linkhttps://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=393fa198-7e07-4162-bd0a-9d873f1544a9&type=display
PubMed IDNA
3-D StructureN.A.
Primary information
ID1767
ThPP IDTh1185
Therapeutic Peptide/Protein NameHuman clostridium tetani toxoid immune globulin
SequenceNA view full sequnce in fasta
Functional ClassificationIIIb
Molecular WeightNA
Chemical FormulaNA
Isoelectric PointNA
HydrophobicityNA
Melting Point (℃)NA
Half LifeNA
DescriptionNA
Indication/DiseaseIt is indicated for prophylaxis against tetanus following injury in patients whose immunization is incomplete or uncertain (see below). It is also indicated, although evidence of effectiveness is limited, in the regimen of treatment of active cases of tetanus.
PharmacodynamicsIt supplies passive immunity to those individuals who have low or no immunity to the toxin produced by the tetanus organism, Clostridium tetani. The antibodies act to neutralize the free form of the powerful exotoxin produced by this bacterium.
Mechanism of ActionNA
ToxicityNA
MetabolismNA
AbsorptionNA
Volume of DistributionNA
ClearanceNA
CategoriesNA
Patents NumberNA
Date of IssueNA
Date of ExpiryNA
Drug InteractionNA
TargetNA
Information of corresponding available drug in the market
Brand NameHypertet S/d
CompanyGRIFOLS USA, LLC
Brand DiscriptionHyperTET® S/D treated with solvent/detergent is a colorless to pale yellow or pink sterile solution of tetanus hyperimmune immune globulin for intramuscular administration; it is preservative-free, in a latex-free delivery system. HyperTET S/D is prepared by cold ethanol fractionation fromthe plasma of donors immunized with tetanus toxoid.
Prescribed forHyperTET S/D is indicated for prophylaxis against tetanus following injury in patients whose immunization is incomplete or uncertain (see below). It is also indicated, although evidence of effectiveness is limited, in the regimen of treatment of active cases of tetanus.
Chemical NameNA
Formulation250 [iU]/mL
Physcial AppearanceInjection
Route of AdministrationIntramuscular
Recommended DosageNA
ContraindicationNA
Side EffectsSlight soreness at the site of injection and slight temperature elevation may be noted at times. Sensitization to repeated injections of human immunoglobulin is extremely rare. In the course of routine injections of large numbers of persons with immunoglobulin there have been a few isolated occurrences of angio neurotic edema, nephrotic syndrome, and anaphylactic shock after injection.
Useful Linkhttps://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=393fa198-7e07-4162-bd0a-9d873f1544a9&type=display
PubMed IDNA
3-D StructureN.A.